We must harness digital technology for 21st-century health care By Karimah Es Sabar. Published on Apr 8, 2021 4:16pm While digital health such as telemedicine doesn’t replace the value of face-to-face contact, disruptive technologies such as real-time, embedded monitoring tools will help health-care specialists track and monitor patients without needing to see them. The federal government s COVID-19 Exposure Notification app for smartphones (Health Canada)
“Hiding within those mounds of data is knowledge that could change the life of a patient, or change the world.” Dr. Atul Butte, Stanford University
These words from Dr. Butte have never been more important. The COVID-19 pandemic has shone a light on many undervalued areas, but most glaringly perhaps is how very important data-sharing and digital health are in delivering health care, now and into the future.
NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity
NeonMind Biosciences Inc. (CSE: NEON) (
NeonMind ), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia where he was previously Professor of Internal Medicine, and he has extensive experience in the design of clinical trials for treatments for eating disorders. He has also been appointed to NeonMind s Board of Advisors.